Addendum
Addendum


Addendum


262

263


Addendum


Addendum


Addendum


415. Weiss GJ, Donehower RC, Iyengar T, Ramanathan RK, Lewandowski K, Westin E et al. Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer. *Invest New Drugs* 2012; 31: 136–144.


Addendum


Addendum


